When Headlines Seed Symptoms: False Memories Inflating Trial Adverse Events
A real-world example of False memory in action
Context
A mid-sized biotech company ran a 12-month Phase II clinical trial of an oral drug for chronic migraine. Partway through, media coverage reported a small number of unrelated adverse events from a different drug class, and patient forums began amplifying anecdotal side effects.
Situation
Trial participants were asked about side effects during monthly phone follow-ups conducted by site coordinators who had just read the news and discussed participants’ concerns. Coordinators used conversational language and occasionally mentioned what other patients had reported on forums.
The bias in action
Over several follow-up calls, participants began reporting side effects they had not experienced before — descriptions mirrored the media stories and forum anecdotes. Some participants later insisted they had felt the same symptoms earlier in the study, even when daily symptom diaries showed no entries for those events. The repetition of suggested symptoms by coordinators and the social exposure to anecdotes led to genuine, but inaccurate, recollections of side effects among a subset of trial subjects.
Outcome
Reported adverse event (AE) incidence rose unexpectedly, triggering an internal safety review and a precautionary pause for enhanced monitoring. The spike slowed enrollment, increased monitoring workload, and created regulatory concern about the drug's safety signal, even though blinded safety data showed no objective increase in biologically plausible events.
What's inside the full case study
Unlock the deeper breakdown with real-world impact, measurable effects, lessons learned, better-approach recommendations, and relevant fields.
Want the full analysis?
Request access to the complete case study, including measurable impact, lessons learned, and the recommended better approach.
